XML 49 R27.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE

The following table summarizes the shares of common stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the years ended December 31, 2024 and 2023 as such shares would have had an anti-dilutive effect:

 

  

   2024   2023 
   As of December 31, 
   2024   2023 
Stock options(a)   31,013    93,892 
Warrants(b)       16,725 
Unvested restricted stock   202,787    144,211 

 

(a)Shares underlying stock options assumed pursuant to the merger agreement with Precision Healing, Inc. (“Precision Healing”) in April 2022.

 

(b)Shares underlying warrants assumed pursuant to the merger agreement with Precision Healing in April 2022.
SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES

Revenue streams from product sales and royalties are summarized below for the years ended December 31, 2024 and 2023.

 

  

   2024   2023 
   For the Year Ended
December 31,
 
   2024   2023 
Soft tissue repair products  $76,125,012   $54,836,410 
Bone fusion products   10,547,413    9,952,432 
Royalty revenue       201,000 
Total Net Revenue  $86,672,425   $64,989,842 
SCHEDULE OF PROPERTY AND EQUIPMENT
  

Useful

Life

  December 31,
2024
   December 31,
2023
 
Computers  3-5 years  $295,963   $194,788 
Office equipment  3-7 years   216,491    201,785 
Furniture and fixtures  5-10 years   346,508    304,338 
Leasehold improvements  2-5 years   181,968    134,170 
Internal use software  5 years       1,618,999 
              
Property and equipment, gross      1,040,930    2,454,080 
Less accumulated depreciation      (608,613)   (1,196,124)
              
Property and equipment, net     $432,317   $1,257,956 
SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION

 

      
Balance at December 31, 2023  $3,823,001 
Change in fair value of earnout liabilities   (1,938,451)
Revaluation of earnout liability   (51,000)
Settlements   (1,085,549)
Balance at December 31, 2024  $748,001